MAIA Biotechnology, Inc. MAIA
Set alert
1.10 USD -0.08 -6.78%
At close · Oct 30
1.10 0.00 +0.38%
After hours · Oct 30, 6:24 PM ET
1.10 Day range 1.17
0.871 52-week range 2.95
- YTD
- -28.10%
- 1 year
- -16.03%
- Open
- 1.16
- Prev close
- 1.18
- Mkt cap
- 67.92M
- Vol
- 313.66K
- Avg vol
- 459.92K
- EPS
- -0.62
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 1.10
- High
- 1.17
- Forward P/E
- -1.25
- Beta
- 0.34
- Short ratio
- 10.99
- Inst. own
- 7.51%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 2.41
- 200-d avg
- 2.83
- 1y target
- 12.63
MAX chart
Events in this range
- Feb 21, 2023Rating: Noble Capital Markets · — → Outperform
Signals (76)
| Name | Date | Ago |
|---|---|---|
| MACD: Sell Signal | Sep 21, 2026 | 1 month ago |
| SMA: Bearish | Aug 24, 2026 | 2 months ago |
| SMA: Bullish | Aug 3, 2026 | 3 months ago |
| MACD: Buy Signal | Aug 3, 2026 | 3 months ago |
| MACD: Sell Signal | Jul 27, 2026 | 3 months ago |
| SMA: Bearish | Jul 13, 2026 | 3 months ago |
| MACD: Buy Signal | Jun 22, 2026 | 4 months ago |
| SMA: Bullish | Jun 15, 2026 | 4 months ago |
| SMA: Bearish | Jun 8, 2026 | 4 months ago |
| SMA: Bullish | May 25, 2026 | 5 months ago |
| MACD: Sell Signal | Mar 16, 2026 | 7 months ago |
| SMA: Bearish | Mar 2, 2026 | 8 months ago |
| SMA: Bearish | Mar 2, 2026 | 8 months ago |
| RSI: Overbought | Jan 19, 2026 | 9 months ago |
| SMA: Bullish | Dec 22, 2025 | 10 months ago |
| MACD: Buy Signal | Dec 15, 2025 | 10 months ago |
| SMA: Bullish | Dec 8, 2025 | 10 months ago |
| MACD: Sell Signal | Oct 13, 2025 | 1 year ago |
| SMA: Bearish | Oct 6, 2025 | 1 year ago |
| SMA: Bearish | Oct 6, 2025 | 1 year ago |
| SMA: Bullish | Sep 29, 2025 | 1 year ago |
| SMA: Bullish | Sep 22, 2025 | 1 year ago |
| SMA: Bearish | Sep 15, 2025 | 1 year ago |
| SMA: Bullish | Sep 8, 2025 | 1 year ago |
| MACD: Buy Signal | Sep 8, 2025 | 1 year ago |
| MACD: Sell Signal | Aug 4, 2025 | 1 year ago |
| SMA: Bearish | Jul 7, 2025 | 1 year ago |
| SMA: Bullish | Jun 30, 2025 | 1 year ago |
| SMA: Bullish | Jun 30, 2025 | 1 year ago |
| SMA: Bearish | Jun 23, 2025 | 1 year ago |
| SMA: Bearish | Jun 23, 2025 | 1 year ago |
| SMA: Bullish | Jun 16, 2025 | 1 year ago |
| SMA: Bullish | Jun 16, 2025 | 1 year ago |
| SMA: Bearish | Jun 9, 2025 | 1 year ago |
| SMA: Bullish | May 26, 2025 | 1 year ago |
| SMA: Bearish | May 19, 2025 | 1 year ago |
| SMA: Bearish | May 12, 2025 | 1 year ago |
| SMA: Bullish | Apr 28, 2025 | 1 year ago |
| SMA: Bullish | Apr 21, 2025 | 1 year ago |
| MACD: Buy Signal | Apr 21, 2025 | 1 year ago |
| SMA: Bearish | Nov 11, 2024 | 1 year ago |
| SMA: Bullish | Nov 4, 2024 | 1 year ago |
| SMA: Bearish | Sep 16, 2024 | 2 years ago |
| MACD: Sell Signal | Jul 22, 2024 | 2 years ago |
| SMA: Bearish | Jul 15, 2024 | 2 years ago |
| SMA: Bullish | Jul 8, 2024 | 2 years ago |
| SMA: Bearish | Jun 17, 2024 | 2 years ago |
| RSI: Overbought | May 13, 2024 | 2 years ago |
| RSI: Overbought | Apr 29, 2024 | 2 years ago |
| SMA: Bullish | Mar 18, 2024 | 2 years ago |
| SMA: Bullish | Mar 11, 2024 | 2 years ago |
| SMA: Bearish | Mar 4, 2024 | 2 years ago |
| SMA: Bullish | Jan 15, 2024 | 2 years ago |
| SMA: Bearish | Jan 8, 2024 | 2 years ago |
| MACD: Buy Signal | Jan 8, 2024 | 2 years ago |
| SMA: Bullish | Jan 1, 2024 | 2 years ago |
| RSI: Oversold | Dec 4, 2023 | 2 years ago |
| MACD: Sell Signal | Nov 20, 2023 | 2 years ago |
| SMA: Bearish | Nov 6, 2023 | 2 years ago |
| SMA: Bullish | Oct 30, 2023 | 3 years ago |
| SMA: Bearish | Oct 23, 2023 | 3 years ago |
| SMA: Bearish | Oct 23, 2023 | 3 years ago |
| SMA: Bullish | Oct 16, 2023 | 3 years ago |
| SMA: Bullish | Sep 25, 2023 | 3 years ago |
| MACD: Buy Signal | Sep 25, 2023 | 3 years ago |
| MACD: Sell Signal | Sep 4, 2023 | 3 years ago |
| RSI: Oversold | Aug 21, 2023 | 3 years ago |
| SMA: Bearish | Jul 31, 2023 | 3 years ago |
| MACD: Buy Signal | Jul 24, 2023 | 3 years ago |
| SMA: Bullish | Jul 17, 2023 | 3 years ago |
| SMA: Bearish | Mar 13, 2023 | 3 years ago |
| SMA: Bearish | Mar 6, 2023 | 3 years ago |
| SMA: Bullish | Jan 9, 2023 | 3 years ago |
| SMA: Bearish | Dec 12, 2022 | 3 years ago |
| RSI: Oversold | Dec 5, 2022 | 3 years ago |
| SMA: Bullish | Oct 31, 2022 | 4 years ago |
Key statistics
- Market cap
- 49.90M
- Enterprise value
- 51.06M
- Trailing P/E
- 0.00
- Forward P/E
- -1.25
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 70.36
- EPS (TTM)
- -1.34
- Beta
- 0.34
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -8.81M
- Total cash
- 11.58M
- Total debt
- 0
- Return on equity
- -559.56%
- Shares outstanding
- 25.33M
- Short % of float
- 3.30%
- 50-day average
- 2.41
- 200-day average
- 2.83
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 12.63 +1047.7% upside
Now 1.10
- Target (low)
- 11.25
- Target (mean)
- 12.63
- Target (high)
- 14.00
Ratings (0m) 1 1 buy · 0 hold · 0 sell
- Strong buy0
- Buy1
- Hold0
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate -0.35.
Financials — quick view
MAIA Revenue — quarterly 0
MAIA Net income — quarterly -7.94M
MAIA EPS — quarterly -0.13
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Feb 21, 2023 | Noble Capital Markets | init | — | Outperform |
About MAIA Biotechnology, Inc.
MAIA Biotechnology, Inc., a targeted therapy, immuno-oncology company, focuses on the development and commercialization of drugs with novel mechanisms of action that are intended to improve and extend the lives of people with cancer. Its lead program is THIO, a potential cancer telomere targeting agent in clinical development for the treatment of NSCLC patients with telomerase-positive cancer cells. The company was incorporated in 2018 and is headquartered in Chicago, Illinois.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- maiabiotech.com
News
- Alpha Buying: 4 Biotech Stocks Insiders Are Betting On
- MAIA Biotechnology Completes Enrollment Of Patients For Part C Of Phase 2 Study Of Ateganosine Sequenced With CPI Cemiplimab To Treat Non-Small Cell Lung Cancer
- MAIA Biotechnology Files Resale Prospectus For 751,879 Shares Issued Under Clinical Trial Funding Agreement
- MAIA Biotechnology Receives Regulatory Approval By The Spanish Agency For Medicines And Medical Devices And Portugal’s National Authority Of Medicines And Health Products To Begin Screening Patients For Its Ongoing Pivotal Phase 3 THIO-104 Clinical Trial In Non-Small Cell Lung Cancer
- MAIA Biotechnology Says First US Patient Dosed In Phase 2 THIO-101 Trial Expansion Evaluating Telomere-Targeting Lead Candidate, Ateganosine, In Third-Line Non-Small Cell Lung Cancer
- MAIA Biotechnology CEO Vlad Vitoc Buys 73K Shares At An Average Price Of $1.37 Per Share; Board Member Ramiro Guerrero Buys 185,078 Shares At An Average Price Of $1.36 Per Share
- 12 Health Care Stocks Moving In Tuesday's After-Market Session
- MAIA Biotechnology Q2 EPS $(0.13) Misses $(0.11) Estimate
- MAIA Biotechnology Reports 90.5% Disease Control Rate In Phase 2 THIO-101 Clinical Trial Of Ateganosine For Advanced Non-Small Cell Lung Cancer
- MAIA Biotechnology Completes Global Enrollment In Part C Of Its Phase 2 THIO-101 Expansion Study Of Ateganosine To Treat Advanced Non-Small Cell Lung Cancer
Your note
Sign in to keep a note on MAIA — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| CHAOUKI STEVEN M | Director | Purchase | Mar 13, 2024 | 88,891 |
| GUERRERO RAMIRO | Director | Purchase | Dec 12, 2024 | 514,970 |
| LOUIE NGAR YEE | Director | Purchase | Apr 24, 2024 | 1,167,190 |
| LUPUT CRISTIAN | Director | Purchase | Oct 31, 2024 | 389,483 |
| MCGUIRE JOSEPH F | Chief Financial Officer | Purchase | Apr 26, 2023 | 9,400 |
| SMITH STAN V | Director | Purchase | Oct 31, 2024 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Group Inc | 2.24% | 566,374 | 1.12M | Sep 29, 2024 |
| Halter Ferguson Financial Inc. | 1.49% | 376,714 | 742.13K | Sep 29, 2024 |
| Geode Capital Management, LLC | 0.76% | 192,563 | 379.35K | Sep 29, 2024 |
| Blackrock Inc. | 0.31% | 79,727 | 157.06K | Sep 29, 2024 |
| Centric Wealth Management | 0.27% | 68,219 | 134.39K | Sep 29, 2024 |
| Bridgeway Capital Management, Inc. | 0.18% | 45,700 | 90.03K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1.59% | 401,588 | 791.13K | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 0.61% | 153,385 | 302.17K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.43% | 108,755 | 214.25K | Oct 30, 2024 |
| Bridgeway Funds Inc-Ultra Small Company Market Fund | 0.18% | 45,700 | 90.03K | Sep 29, 2024 |
| Fidelity Total Market Index Fund | 0.14% | 36,051 | 71.02K | Oct 30, 2024 |
| iShares Micro Cap ETF | 0.12% | 29,164 | 57.45K | Oct 30, 2024 |